BioCentury
ARTICLE | Emerging Company Profile

Essa: A baby Cougar

Essa's EPI-0011 kills prostate tumors other androgen-targeting agents don't

May 7, 2012 7:00 AM UTC

Essa Pharma Inc. is developing a next-generation hormone antagonist that blocks a previously intractable androgen receptor domain, a strategy the company expects to work in advanced castration-resistant prostate cancer even after other androgen receptor blockers have failed.

Prostate cancer cells depend on androgen to replicate and grow. Androgen deprivation therapy is therefore used to treat the roughly 30% of men whose prostate cancer recurs following surgery and/or radiation...